Schematic image of NK cell-engaging nanodrones (NKeNDs).
CREDIT: UNIST
A groundbreaking study led by Professor Sebyung Kang and Professor Sung Ho Park in the Department of Biological Sciences at UNIST has unveiled a remarkable breakthrough in cancer treatment.
The research team has successfully developed unprecedented “NK cell-engaging nanodrones” capable of selectively targeting and eliminating cancer cells, offering a potential solution for intractable types of cancers.
The innate lymphoid cells known as natural killer (NK) cells play a vital role in the body’s immune response against cancer. Numerous efforts have been made to harness the power of NK cells to develop effective cancer therapies. Now, the research team has designed and fabricated exceptional NK cell-engaging nanodrones, referred to as NKeNDs, using AaLS protein cage nanoparticles.
These groundbreaking NKeNDs simultaneously display cancer-targeting ligands, such as HER2Afb or EGFRAfb, and NK cell-recruiting ligands, aCD16Nb, on the surface of the AaLS through the SpyCatcher/SpyTag protein ligation system. The dual ligand-displaying NKeNDs, named HER2 @NKeND and EGFR@NKeND, have demonstrated the ability to selectively bind to HER2-overexpressing SK-OV-3 cells and EGFR-overexpressing MDA-MB-468 cells, respectively, as well as human NK cells.
The physical engagement of human NK cells with the target cancer cells mediated by the NKeNDs activates the NK cells, enabling them to effectively eliminate the target cancer cells in vitro. Remarkably, in SK-OV-3 tumor-bearing mice, the administration of HER2 @NKeNDs along with human PBMCs facilitates the infiltration of activated human NK cells into the tumor sites. As a result, tumor growth is significantly suppressed without causing noticeable side effects.
This groundbreaking study showcases a novel approach to developing cancer-specific NK cell engagers by utilizing protein cage nanoparticles and recombinant cancer cell binders. It offers tremendous potential for the selective treatment of previously intractable types of cancers.
Professor Kang Se-byung expressed his excitement about the study, stating, “This research presents new possibilities for immune treatment through NK cell delivery nanodrones, overcoming challenges such as the movement and survival of NK cells. We aim to provide new opportunities for customized treatments that selectively address various types of cancer through further research, including cancer-specific immune cell induction.”
Original Article: Revolutionary nanodrones enable targeted cancer treatment
More from: Ulsan National Institute of Science and Technology
The Latest Updates from Bing News
Go deeper with Bing News on:
NK cell-engaging nanodrones
- Use of Allogeneic NK Cells for Cancer Immunotherapy
Following the discovery of inhibitory KIR and the understanding that they play a role in preventing NK cell killing of self MHC I-expressing tumor cells, investigators began to research the ...
- Use of Allogeneic NK Cells for Cancer Immunotherapy
Overview of current approaches to improve effectiveness of adoptive transfer of NK cells by manipulation of the NK cell product, the host and the target. Human NK cells are a subset of peripheral ...
- Having lost Merck partnership, Artiva looks to IPO to fund NK cell therapy
The biotech does maintain another partnership in the form of Affimed. The two companies agreed in November 2022 to evaluate combining Affimed’s innate cell engager AFM13 with one of Alumis’ NK ...
- Boosting ‘natural killer’ cell activity could improve cancer therapy
CAR-T cell therapy is also patient-specific in that a patient’s own T cells have to be used. But a novel treatment known as CAR-NK therapy, which uses natural killer cells rather than T cells, is now ...
- From Culture to Clinic: Scale Up NK Cell Expansion
Building on the success of CAR T cell therapy for treating blood cancers, researchers are developing NK cell therapies that employ the natural ability of these immune cells to eliminate abnormal cells ...
Go deeper with Bing News on:
Targeted cancer treatment
- Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals ...
- Budget 2024: Doctors welcome decision to exempt 3 cancer drugs from customs duty
The government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil ...
- Presurgical Targeted Therapy, Immunotherapy Show Responses in Melanoma
Researchers have found that among patients with certain melanoma, presurgical targeted therapy and immunotherapy can result in better pathologic response.
- Preclinical study shows promise of systemic targeted therapy in a rare form of cancer
Pseudomyxoma peritonei is a rare and poorly understood cancer, characterized by the progressive accumulation of mucin in the abdominal cavity. Mainstay treatments are surgery and chemotherapy but ...
- Deciphering the role of RET in cancer and breakthroughs in targeted treatments
Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...